Kornimate/medical-research-clean huggingface dataset:
physical activity, sports and health in adults with intellectual disabilities

Conditions: Intellectual Disability

Summary: currently, there is a paucity of quality research within the field of health science with a focus on persons with intellectual disabilities, and especially how longer lasting periods of varied physical activity affects the target group. there is a lack of insight, in how persons with intellectual disabilities learns and retains movement skills. thus, the research group behind this project will investigate the following research questions: 1. does 40 weeks of intense and varied sports and physical activities as an intervention lead to positive changes in health status for adults with intellectual disabilities? 2. can lasting effects be measured three and six months after the intervention? 3. does the intervention improve the motor competences for the participants? 4. how does defined groups of adult persons with down syndrome and cerebral palsy learn and retain a new motor skill?


Eligibility criteria:
inclusion criteria: * presence of an intellectual disability exclusion criteria: * participants under guardianship * unable to give informed consent to participate on their own

Keywords: intellectual disability physical activity cardiovascular fitness bone health body composition
clinical impact of different duration prone postition treatment for patients with ards.

Conditions: Oxygenation; Driving Pressure

Summary: acute respiratory distress syndrome (ards) is a life-threatening disease, patients with ards usually need mechanical ventilation. the treatment of ards include low tidal volume ventilation, steroid, extracorporeal membraneous oxygenator, inhaled nitric oxide or prone position . some studies showed prone position had beneficial effect of oxygenation and mortality for severe ards patients, the duration of prone position should be at least 10 hours. it is unknown the optimal duration of prone position which is better for severe ards patients. this study will compare the clinical differences of 16-hour and 24-hour prone position for severe ards patients.

this is a prospective randomized controlled study. all severe ards patients were eligible for screening from january 2020 to december 2022. inclusion criteria include: patient above 20 year-old with diagnosis of severe ards under protective lung ventilation( tidal volume 4-8 ml/kg, plateau pressure \ 60%）. patients were excluded if patients were not intubated and mechanically ventilated or contraindication for prone position ventilation (intracranial hemorrhage, massive hemoptysis, unstable hemodynamic status, recent pacemaker implantation, severe facial laceration, open abdominal wound, spine, femur or pelvis fracture or pregnancy). patients will divide into 2 groups, one is patients supported by 16-hour prone position; another group is patients with 24-hour prone position, each group enrolled 30 patients. the medical records of these patients were analyzed for age, gender, body weight, diagnosis, pulmonary or extrapulmonary ards, acute physiology and chronic health evaluation (apache) ⅱscore, days between ards to prone position, icu day, hospital day, ventilator day, pre and post prone position vital signs, laboratory data including arterial blood gas, lactate, respiratory parameters included pao2/fio2, peak inspiratory pressure, positive end-expiratory pressure, ventilator mode, steroid treatment, complications (tube dislodge, pressure sore, infection), and mortality outcomes. the primary endpoint is the difference of oxygenation (pao2/fio2), the secondary endpoint are other respiratory parameters, vital signs, icu day, hospital day, ventilator day, complications and survival.

Eligibility criteria:
inclusion criteria: * patient above 20 year-old with diagnosis of severe ards under protective lung ventilation (tidal volume 4-8 ml/kg, plateau pressure \ 60%). exclusion criteria: * patients were not intubated and mechanically ventilated or contraindication for prone position ventilation (intracranial hemorrhage, massive hemoptysis, unstable hemodynamic status, recent pacemaker implantation, severe facial laceration, open abdominal wound, spine, femur or pelvis fracture or pregnancy).

Keywords: acute respiratory distress syndrome mechanical ventilation oxygenation prone position protective lung ventilation
long-term prognosis of patients with hepatitis b related acute-on-chronic liver failure

Conditions: Hepatitis B; Acute-On-Chronic Liver Failure

Summary: this study is to investigate the long-term outcomes and prognostic risk factors in patients recovered from hepatitis b virus related acute on-chronic liver failure.

chronic acute liver failure (aclf) is a systemic multi-organ failure driven by acute liver injury in the basis of chronic liver disease. the main cause of chronic acute liver failure in china is hepatitis b virus infection.previous studies on the prognosis of acute on-chronic liver failure mainly focused on the short-term survival rate and the follow-up time was relatively short, while the study on the long-term prognosis of patients with spontaneous recovery of chronic acute liver failure was still lack-ing. thus,this study mainly retrospectively analyzed the clinical data of patients with chronic hepatitis b related acute liver failure admitted to the department of infectious diseases, the third affiliated hospital of sun yat-sen university, and con-ducted telephone follow-up survey to analyze the long-term prognosis of patients with chronic hepatitis b related acute on-chronic liver failure.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years old; * the diagnosis consistent with hepatitis b associated chronic acute liver failure； * after hospitalization, the survival time \> 90 days； * the inpatient clinical data are complete. exclusion criteria: * human immunodeficiency virus infection or congenital immune deficiency diseases; * liver cancer and other tumors, autoimmune liver disease, genetic and metabolic liver disease, or other serious diseases that significantly affect patient survival; * other conditions that the researchers judged not appropriate for inclusion.

Keywords: hepatitis b acute-on-chronic liver failure prognosis
study evaluating efficacy and safety of crisaborole in adults with stasis dermatitis

Conditions: Stasis Dermatitis

Summary: this is a phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment 2% or vehicle twice daily for 6 weeks.

study c3291038 is a phase 2a, randomized, double-blind, vehicle-controlled, parallel-group, proof of concept study to evaluate the efficacy, safety, and local tolerability of 6 weeks of treatment with crisaborole in adult participants with sd without active skin ulceration. approximately 70 eligible participants will be randomized into the double blind treatment period in a 1:1 ratio to receive crisaborole ointment, 2% or vehicle twice daily for 6 weeks. the study will recruit male and female participants aged ≥ 45 years with a clinical diagnosis of sd. the total duration of participation in the study will be up to 14 weeks, including up to 4 weeks for screening, a 6 week double blind treatment period, and a follow-up period of 4 weeks after treatment completion. study enrollment and management will be de centralized, where participants do not visit an investigator or a clinic for clinical assessment. the participants will participate in the study at home. the sponsor (or designee) will provide home visits by qualified home visit practitioners (hvp), remote contact by telemedicine (or telephone), and clinical database electronic case report forms (ecrfs), ediary, and other electronic data entries from 3rd party vendors for study data collection.

Eligibility criteria:
inclusion criteria: * participants who are ≥45 years of age and in generally stable health * participants who are in generally stable health and have a known diagnosis of stasis dermatitis or newly diagnosed stasis dermatitis * participants whose mental and physical status allows them to be able to mostly perform their activities of daily living with minimal assistance exclusion criteria: * participants with clinically significant active or potentially recurrent dermatitis conditions and known genetic dermatological conditions that are not stasis dermatitis or overlap with stasis dermatitis * participants with active venous stasis ulceration on either lower extremity. * participants with current infection or suspected infection of any stasis dermatitis lesions * women of child bearing potential (wocbp) are not eligible for this study

Keywords: stasis dermatitis venous hypertension venous insufficiency
assessing chronic pain conditions in general population

Conditions: Chronic Pelvic Pain

Summary: the purpose of this study is to determine the percentage of women, among those attending our institute in order to do pap test, suffering of chronic pelvic pain. to such purpose the patients will be submitted to questionnaires.


Eligibility criteria:
inclusion criteria: * women over 18 years of age exclusion criteria: * unwilling or unable to give consent
evaluation of hand functions in newly diagnosed primary sjögren's syndrome

Conditions: Sjogren's Syndrome

Summary: hand functions are decreased in rheumatic diseases such as systemic sclerosis and rheumatoid arthritis. sjögren's syndrome (ss) is a chronic systemic rheumatic disease characterized by lymphoplasmacytic infiltration of exocrine glands, especially salivary and lacrimal glands. ss may be "primary" when it occurs alone (pss) and "secondary" (sss) when associated with another autoimmune disease. pss is the most common connective tissue disease after rheumatoid arthritis and affects 0.3-3% of the population. joint involvement is the most common involvement of pss after sicca syndrome (50% of patients). patients may have arthralgia with inflammatory features (morning stiffness \> 30 minutes) or, less frequently, true symmetric polysynovitis mimicking rheumatoid arthritis (ra). the joint involvement of pss is usually moderate (\<5 affected joints) and mostly affects the small joints of the hands and upper extremities. pss may also be responsible for myositis. widespread pain, similar to primary fibromyalgia, is common in about 50 percent of patients with pss. the hand is one of the most important components affecting the functionality of the upper extremity. grasping is one of the hand functions, for the continuity of daily living activities. is an important function. studies have shown that hand grip strength is correlated with upper extremity muscle strength, as well as general body muscle strength and pulmonary muscle strength. as far as we know, hand functions have not been evaluated in newly diagnosed patients with pss.


Eligibility criteria:
inclusion criteria: * 1. patients aged 18-65 years diagnosed with primary sjogren's 2. patients with normal cognitive functions exclusion criteria: * 1. other connective tissue diseases other than primary sjögren's 2.pregnancy 3.malignancy 4. chronic diseases (dm, ht, hypothyroidism, hyperthyroidism) 5. cognitive disorder 6. neurological or traumatic hand disorders leading to hand disorders (ms, trauma, svo) 7. patients who have undergone major salivary gland surgery, have graft versus host disease, have received sarcoidosis, head and neck radiotherapy, have a history of htlv-1 or hiv
clinical study on electroacupuncture therapy for chronic neck pain

Conditions: Neck Pains

Summary: purpose of this test is to observe and objectively evaluate electroacupuncture (ea) therapy on the clinical efficacy in patients with chronic neck pain, and provide a reliable clinical basis for the chronic neck pain treatment and evaluation of efficacy.

according to statistics, the incidence of chronic neck pain has significantly increased year by year, particularly tending to younger people, as social competition increase fiercely and the pace of people's daily work and life accelerate. studying the effective treatment and prevention of chronic neck pain has obvious medical, social and economic significance. purpose of this trial is to observe and objectively evaluate electroacupuncture (ea) therapy on the clinical efficacy in patients with chronic neck pain, and provide a reliable clinical basis for the chronic neck pain treatment and evaluation of efficacy.

Eligibility criteria:
inclusion criteria: 1. age of a subject is older than 18 and is younger than 65. 2. with more than 3 months history of neck pain. 3. informed consent is signed by a subject or his lineal relation. exclusion criteria: 1. with serious protopathy or disease ofcardiovascular,liver,renal,gastrointestinal, hematological systems and so on. 2. psychotic，patients with allergic constitution or easily getting infected or bleeding. 3. patients have used drugs for preventing neck pain in the last four weeks. 4. pregnant women or women in lactation.

Keywords: electroacupuncture therapy neck pain mcgill pain questionnaire acupuncture therapy electroacupuncture meridians
ethanol-lock therapy for the prevention of non-tunneled catheter-related infection in pediatric patients

Conditions: Infection, Catheter-Related; Central Line-associated Bloodstream Infection (CLABSI); Pediatric

Summary: central venous catheter (cvc) infection is a common complication in pediatric patients, resulting in prolonged length of stay in hospital, requiring antibiotics, invasive procedures and increase morbidity and mortality. given the repercussion of this complication, measures that minimize its should be stimulated. the purpose of this study is to evaluate the effects of intraluminal alcoholization (ethanol lock therapy) on prevention of infection of short-term central venous catheters in pediatric patients.

the patients was divided into two groups, where one received alcoholization (ethanol lock therapy group) and the other not (control group). the variables evaluated were: clabsi, etiological agents, adverse events and the mechanical effects of ethanol on the catheter (breakage and obstruction). to determine the association between the independent variable and the dependent variables, the chi-square test of association (pearson) and fisher's exact test were used. the risk ratio (rr) was calculated as a relative risk measure, with its 95% confidence interval (95% ci). the significance level of 5% was adopted. the sample size calculation was performed in the openepi software version 2.3.1. and a long-term catheter clinical trial was used to calculate the sample size, which demonstrated a 9% central venous catheter infection frequency in the ethanol group and 37% in the control group, so that the sample size was 80 patients (40 in each group), considering a power of 80%, an alpha error of 5% and 10% of post-randomization losses.

Eligibility criteria:
inclusion criteria: * pediatric surgery patients; * weight: 2 kg or more; * using non-tunneled double-lumen polyurethane central venous catheter; * cvc inserted at operation room, pediatric intensive care unit (picu) or neonatal intensive care unit (nicu); * cvc adequately positioned (checked by radioscopy ou radiography); * cvc implanted within a maximum of 24 hours. exclusion criteria: * patients whose catheters had been inserted under emergency situations; * patients in a critical condition (those requiring continuous fluid/drug infusion through both lumens); * patients with a history of hypersensitivity or allergic reactions to ethanol were excluded from the study.

Keywords: central venous catheters child ethanol therapy clabsi
operative versus non operative treatment of proximal humerus (shoulder joint) fractures

Conditions: 3 and 4 Part Proximal Humerus Fractures

Summary: to determine if operative treatment of non operative management of these fractures is best. hypothesis: there is no difference in functional outcome between operative and non-operatively treated 3- and 4-part proximal humerus fractures at one year's time.

participants of 70 years of age or older who have been medically assessed as 'fit for surgery' are randomly (like flipping a coin) to either operative or non operative management of their injury. clinical follow-up including x-rays, and physical assessment of injured shoulder, and outcomes questionnaires will be used to determine which if either resulted in the best outcome.

Eligibility criteria:
inclusion criteria: * proximal humerus fracture patients

Keywords: operative non operative
effect of rifampin on the pharmacokinetics of linifanib in subjects with advanced or metastatic solid tumors

Conditions: Advanced Solid Tumors

Summary: this is a phase 1, open-label study designed to determine the interaction of rifampin with linifanib.

this study is designed to explore the drug interaction between rifampin and linifanib to determine the potential effect of rifampin on the metabolism of linifanib. linifanib will be taken alone or in combination with rifampin. the safety of a single dose administration of linifanib when administered alone and in combination with rifampin will be assessed. subjects may enroll in a separate extension study to continue receiving linifanib after completion of this study.

Eligibility criteria:
inclusion criteria 1. age is greater than or equal to 18 years. 2. subject must have a histologically or cytologically confirmed non-hematologic malignancy other than hcc. 3. eastern cooperative oncology group (ecog) performance score of 0-2. 4. subject must have adequate bone marrow, renal and hepatic function. * bone marrow: absolute neutrophil count (anc) \>= 1,500/mm\^3 (1.5 x 10\^9/l); platelets \>= 75,000/mm\^3 (75 x 10\^9/l); hemoglobin \>= 9.0 g/dl (1.4 mmol/l) * renal function: serum creatinine \<= 2.0 mg/dl (0.81 mmol/l); * hepatic function: ast and alt \<= 1.5 x uln unless liver metastases are present, then ast and alt \<= 5.0 x uln; bilirubin \<= 1.5 mg/dl (0.026 mmol/l). 5. subject must have partial thromboplastin time (ptt) \</= 1.5 x upper limit of normal ( uln) and international normalized ratio (inr) \</= 1.5. exclusion criteria 1. subject has received anti-cancer therapy including investigational agents, cytotoxic chemotherapy, radiation therapy or biologic therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to study drug administration. in addition subject has not recovered to less than or equal to grade 1 clinically significant adverse effects/toxicities of the previous therapy. 2. subject has undergone major surgery within 21 days of study day 1. 3. subject has untreated brain or meningeal metastases. subjects with treated brain metastases that are radiographically or clinically stable (for at least 4 weeks after therapy) and who have no evidence of cavitation or hemorrhage in the brain lesion, are eligible provided that they are asymptomatic and do not require corticosteroids (must have discontinued steroids at least 1 week prior to study day 1). 4. subject has received potential inhibitors of the metabolism of linifanib within 21 days prior to initial study drug administration. such drugs include cyp3a inhibitors, cyp1a2 inhibitors, cyp2c19 inhibitors, cyp2c8 substrates and cyp3a inducers. 5. current enrollment in another clinical trial..
comparing high and normal protein diets for the dietary remission of type 2 diabetes

Conditions: Diabetes Type 2; Obesity; Diet Modification

Summary: the purpose of this study is to examine the impact of high protein (hp) vs. normal protein (np) diets on weight loss, loss of fat free mass (ffm), and remission of type 2 diabetes (t2d) in individuals with t2d. both diet groups will receive dietary and physical activity guidance through a group-based weight loss program, state of slim (sos). the central hypothesis is that the hp diet (with ≥4 weekly servings of lean beef) will lead to greater remission of t2d vs. a np diet by 1) producing greater weight loss and limiting weight regain and 2) preferentially reducing fat mass while preserving ffm.


Eligibility criteria:
inclusion criteria: * male or female * age ≥18 years * t2d diagnosis within previous 6 years (documented physician diagnosis, use of antidiabetic medication, fasting glucose ≥126 mg/dl, and/or hba1c ≥6.5%) * bmi of ≥27 kg/m2 * weight stable (±3kg in the last 3 months) * participants using glp-1 agonists or slgt-inhibitors must be on a stable (≥3 months) medication dosage and not be planning to change medication dosage * willing and able to participate in a weekly group class for the first 16 weeks of the study, bi-weekly classes for the remainder of the study, and willing to participate in 4 study visits over the 52 week study period. exclusion criteria: * hba1c concentration of ≥12%. * pregnant or lactating within the past 6 months or trying to become pregnant. * individuals following a vegetarian/vegan only diet * food allergies (to red meats or other common protein sources) * using exogenous insulin for t2d management * taking other medications that could cause weight loss or weight gain (such as steroids, tricyclic antidepressants, chemotherapy, antipsychotics, prescribed or otc weight loss agents). oral contraceptives can be used as long as subject agrees to not change use of these during the study. vitamins and minerals that do not have a weight effect are allowed as long as use is continued without change during the study. * current alcohol or drug abuse or dependence (subjects who have quit smoking in the last 6 months will be excluded. smokers whose smoking habits have been stable for the last 6 months and which remain stable during the study can be included). * current eating disorder (anorexia or bulimia) * any medical condition for which following a high protein diet and/or 70 minutes of exercise daily would be inadvisable. * untreated or unstable hypothyroidism. thyroid medications must be stable for at least 3 months.

Keywords: weight loss dietary protein